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Abstract
Background: The purpose of this study was to examine proliferative and apoptotic activity in relation with BRCA1
expression in ovarian epithelial inclusions (OEIs), the putative precursor lesions of ovarian epithelial cancer (OEC).
Methods: Benign ovaries from 95 patients were examined. Dual immunohistochemical staining for both BRCA1
and MIB-1 were performed to examine the relationship between BRCA1 and MIB-1 in OEI cells. Apoptotic activity
was assessed on the parallel tissue sections by using TUNEL assay. Patients’ age, menstrual phase and menopausal
status were analyzed.
Results: OEIs were present in the ovaries of 53% of the patients. OEIs were less frequently found in premenopausal
(45%) than postmenopausal women (58%). BRCA1 and MIB-1 were found in 27 and 47% of the OEI-containing
ovaries, respectively. All BRCA1 positive OEI cells are MIB-1 positive with dual staining method, although overall the
percentage of positive cells was small. No significant difference was found for BRCA1 and MIB-1 expression in OEIs
between menopausal status and menstrual phases. Apoptosis containing OEIs were seen in 70% of the ovaries.
Compared to OEIs in proliferative menstrual phase and premenopausal status, significantly more apoptosis was
found in OEIs from secretory phase and postmenopausal women. A small fraction of the epithelial cells within OEIs
are proliferating or dying.
Conclusions: Low estrogen and/or high progesterone levels may promote OEI cell turnover via induction of apoptosis.
Imbalance between cell proliferation and death within OEIs under influence of hormones may play a role in the ovarian
epithelial tumorigenesis.
Keywords: Ovarian cancer precursors, Ovarian epithelial inclusions, BRCA1, Ovarian epithelial proliferation and apoptosis
Background
Epidemiological studies show a clear trend of significantly
decreasing risk of ovarian epithelial cancer (OEC) with
increasing numbers of pregnancies, duration of oral
contraceptive [1] use, and duration of breast-feeding [2].
These protective factors interrupt ovulation and associ-
ated cyclic hormonal changes, but the molecular mecha-
nisms accounting for the protective effects are unknown.
Hypotheses that have been suggested to explain these
observations from different angles including ‘incessant
ovulation’ and ‘imbalanced levels of gonadotropins and
sex-steroid hormones’ [3].
The incessant ovulation hypothesis put forward by
Fathalla [4] proposes that OEC risk is essentially deter-
mined by the increased proliferative activity of the ovarian
surface epithelium (OSE) required to accomplish repair of
the ovarian surface after each ovulation. It is supported by
experiments in which repeated culture of rat ovarian
epithelial cells resulted in their acquiring malignant
features and the production of serous adenocarcinomas
when injected into nude mice [5–7]. The incessant ovula-
tion hypothesis provides a quantitative explanation of the
decreasing risk with pregnancies, OC use and breast
feeding [8]. But it cannot explain the continuing increase
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in OEC rates after menopause or the much reduced inci-
dence rates of OEC in Asian women [8].
A simple incessant ovulation hypothesis also does not
provide a satisfactory explanation for the observation
that most early stage OECs are found within the ovary
rather than on its surface [9]. This observation has led
most investigators to conclude that OECs arise princi-
pally from ovarian epithelial inclusions (OEIs) rather
than directly from the OSE [9], but additional evidence
for this hypothesis has been difficult to produce. Mittal
et al., [10] studied contralateral ovaries from 42 women
with unilateral ovarian cancer and compared them to
ovaries from age-matched controls. They reasoned that
if OEC did arise from OEI, then these contralateral ovar-
ies from OEC patients should have increased numbers
of OEIs, and they actually found this in their study.
Presence of OEI is also associated with the development
of OEC [11]. However, three other similar studies failed
to confirm this [12–14]. Increased numbers of OEI have
been found in ovaries from women with a strong familial
history of ovarian cancer than in ovaries from control
women in two studies [15, 16]. It is, however, difficult to
judge the significance of these results as these studies
also found multiple other ‘abnormalities’ in the ovaries
of the women with a family history of ovarian cancer.
More recently, understanding the cell of origin of OECs,
particularly ovarian serous carcinomas, have been
significantly improved. It is currently believed that the
majority of ovarian serous carcinomas are derived from
fallopian tubal epithelial cells [17, 18].
OEIs were previously thought to arise from entrapment
of the ovarian surface after ovulation, but our recent stud-
ies showed that the majority OEIs are actually derived
from fallopian tubes [17, 19–21] . The OEIs from fallopian
tube is also known as endosalpingiosis. From that perspec-
tive, OEIs or endosalpingiosis are now considered as
precursor lesions of OECs. It may, therefore, be more
relevant to study the proliferative and apoptotic rate of
OEI cells than the number of OEIs, since there is much
evidence that cell proliferation and apoptosis are strongly
associated with cancer development and progression [22].
If OEI cells do give rise to OECs, it will be then very
reasonable to hypothesize that epithelial proliferation is
increased and/or apoptosis is reduced in OEIs in the post-
menopausal compared to the premenopausal period since
there is a much slower increase in ovarian cancer risk in
the postmenopausal period [8].
Women who carry BRCA1 mutations are at a signifi-
cantly increased risk for ovarian cancer [1] and high
prevalence of OEIs have been found in prophylactically
removed ovaries of BRCA mutation carriers [23]. BRCA1
behaves like a tumor suppressor gene with DNA repair
function [24]. If OEIs are the site of OEC development
then dividing OEI cells may express BRCA1 to exert its
protective effect against the development of OEC. We
previously reported that BRCA1 expression paralleled cell
proliferation in benign and borderline ovarian epithelial
tumors, but not in ovarian epithelial cancers [25]. Spor-
adic ovarian cancer showed significantly reduced levels,
rather than complete loss, of BRCA1 expression [25].
More interestingly, OEI or endosalpingiosis has also been
linked to the development of pelvic serous carcinoma in
women who are BRCA mutation carriers in one of our
recent studies [26].
In this paper, we describe our findings on the occur-
rence of OEIs, and on cell proliferation, cell apoptosis,
and BRCA1 expression of OEI epithelial cells in ‘normal’
ovaries from women with no known history of familial
ovarian cancer. Age, menopausal status, and menstrual
phase were considered in the analysis.
Methods
Patients and tissue sections
‘Normal’ ovaries from 95 patients of known menopausal
status were obtained from the files of the Department of
Pathology, University of Arizona. A total of 190 ovaries
were obtained at total abdominal hysterectomy and
bilateral salpingo-oophorectomy for benign conditions
(but excluding benign ovarian tumors) during the period
2010 through 2015. Patients studied were without a
known family history of breast or ovarian cancers.
Approval for use of these tissues was obtained from the
Institutional Review Board of the University of Arizona.
Two sections or more from each ovary were examined
for the presence of OEIs. If both ovaries from a single
patient contained OEIs, we arbitrarily chose one of the
ovaries for the study. The number of OEIs in each
section was recorded separately. Although ovaries from
50 patients showed the presence of OEIs, we studied
MIB-1 and BRCA1 expression in ovaries of 30 patients
due to limited tissue availability.
Menstrual phase was determined based on micro-
scopic examination of the endometrium from hysterec-
tomy specimens. Menopausal status was obtained from
clinical charts.
Immunohistochemical (IHC) analyses and dual stainings
Representative sections containing OEIs were stained with
dual markers of BRCA1 and MIB-1. Mouse monoclonal
antibody against human BRCA1 protein (Ab-1, IgG2a)
generated from amino acid sequence 1–304 of BRCA1
was obtained from Oncogene Research Products
(Cambridge, MA). The specificity of this BRCA1 anti-
body has been characterized previously [25]. MIB-1
(Ki-67 paraffin), a mouse monoclonal antibody (IgG1)
recognizing a nuclear antigen expressed in all cell cycle
phase except G0 [27], was obtained from Immunotech,
Inc. (Westbrook, ME). Five-micrometer parallel sections
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of the ovaries containing OEIs were cut and placed on
Super Plus slides (Fisher Scientific, Pittsburgh, PA) for
IHC. A section of each specimen was stained with
hematoxylin and eosin (H&E) and examined microscopic-
ally for the presence of OEI and to confirm that the ovar-
ian specimen was otherwise benign. The dual staining
procedure was described elsewhere [28]. Briefly, the first
(BRCA1) IHC staining was performed on formalin-fixed
and paraffin-embedded sections using the streptavidin-
biotin-peroxidase methodology and the second (MIB-1)
was done with alkaline phosphatase. The antigens were
unmasked with the heat-mediated antigen retrieval
method as described previously [25]. Specific signal of
BRCA1 was visualized by incubation with peroxidase
coupled rabbit anti-mouse IgG for 120 min, followed by
incubation with Diaminobenzidine as chromogen creating
a brown nuclear staining product. Then MIB-1 IHC was
performed as described previously [25] by using alkaline
phosphatase coupled secondary antibodies. Subsequent
color development with phosphate substrate created a
bright red product. An orange color was observed when
both BRCA1 and MIB-1 stained the same cell nuclei
(double nuclear staining). Five hundred OEI epithelial cells
per ovary were counted to generate the percentage of
positive cells.
Controls for the IHC were as follows: MCF-7 breast
cancer cells and the developing follicles in human
ovarian sections served as positive controls for BRCA1
expression [29]. Internal positive controls were evaluated
by utilizing areas of folliculogenesis when ovaries were
from premenopausal women. Ab1 BRCA1 antibody was
also validated in two ovarian cancers containing germ-
line BRCA1 del185AG mutations. This specific mutation
results in the deletion of most of the protein, including
the Ab-1 epitope. As expected, no BRCA1 immunoreac-
tivity was detected in these two cases. Cytokeratin IHC
was done in all BRCA1 negative cases to rule out false
negatives. Proliferative endometrial tissue sections served
as positive controls for MIB-1 staining. Negative controls
were carried out by replacing primary antibodies with
class matched mouse IgGs on parallel ovarian sections.
Detection of apoptosis
Parallel sections from the above mentioned 30 ovaries
were examined for apoptosis by using terminal deoxynu-
cleotidyl transferase-mediated deoxyuridine triphosphate
nick end labeling (TUNEL) assay. The TUNEL proced-
ure was previously described [30]. The ApopTag In situ
Apoptosis Detection Kit (Oncor, Gaithersburg, MD) was
used and the procedure protocol recommended by the
manufacturer was followed. Briefly, deparaffinized and
hydrated slides were treated with proteinase K (20 μg/ml)
for 15 min at room temperature. Slides were thoroughly
washed in PBS then treated with 2% hydrogen peroxide
for 5 min to bleach the endogenous peroxidase activity.
Samples were then subjected to 3’-end labeling of DNA
with digoxigenin-dUTP utilizing TdT enzyme in a hu-
midifier chamber at 37 °C for 60 min. This was followed
by incubation with conjugated anti-digoxigenin peroxidase
antibody. Sections were developed with diaminobenzidine
tetrahydrochloride substrate, counter-stained, dehydrated,
cleared and mounted. Apoptotic cells were assessed in the
epithelial compartment only under light microscopic
examination. Apoptotic cells were counted based on their
golden brown stained, condensed, lobulated, and fragmen-
ted nuclei. A total of 500 cells were counted in high power
fields (400×) and the percentage of apoptotic cells was
determined.
Data evaluation and statistical analysis
Ovaries with or without positively stained cells for each
assay (MIB-1, BRCA1 and TUNEL) were calculated and
recorded. The number of OEIs from each ovary was also
recorded. A total of 500 cells were counted in high
power fields (400×) and the percentage of positively
stained (MIB-1 and BRCA1) and apoptotic cells was
determined by counting the OEI cells in the stained
sections in a random fashion. Based on the obtained
data, the average percentage of positive cells detected by
the above mentioned assays in each OEI was calculated
and compared in different age groups.
The data were analyzed by standard contingency table
methods and non-parametric Mann-Whitney U-tests
using the EPILOG (Epicenter Software, Pasadena, CA)
and StatView (SAS Institute, Cary, NC) computer pack-




OEIs were present (in the two sections examined) in the
ovaries of 50 (53%) of the 95 patients with an average of
0.99 inclusions (range 0–13) per ovarian section exam-
ined. The presence of OEIs (from the sum of 2 sections)
in the paired ovaries were highly correlated, 44 (88%) of
the 50 cases with OEIs had OEIs in both ovaries. OEIs
were found slightly less frequently in ovaries from pre-
menopausal women (18/40, 45%) than in ovaries from
postmenopausal women (32/55, 58%) (Table 1); the aver-
age numbers of OEIs per ovarian section examined were
0.65 and 1.25 in premenopausal and postmenopausal
women, respectively. There was no clear trend with age
in premenopausal women. In premenopausal women in
the age groups 20–34, 35–44, and 45–54, the presence
of OEIs were: 4/6 (67%), 3/12 (25%) and 11/22 (50%),
respectively. The average numbers of OEIs per ovarian
section examined for each age group were 1.08, 0.25 and
0.75, respectively. In postmenopausal women there was
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a much greater number of OEIs in the age group 45–54
than in older groups. In the age groups 45–54, 55–64,
and 65–79, the presence of OEI was 14/18 (78%), 11/21
(52%), and 7/16 (44%), respectively. The average number
of OEIs per ovarian section examined was 2.25, 0.89
and 0.58, respectively. The average number decreased
significantly with age among postmenopausal women
(p = 0.001) from age group 45–54 to 65–79.
MIB-1 and BRCA1 expression in OEIs
We examined MIB-1 immunoreactivity in OEI cells from
30 OEI-containing ovaries, among which MIB-1 was
found in OEI cells from 14 (47%) ovaries. Premenopausal
OEI-containing ovaries showed greater proportion of
positive immunoreactivity (7/13, 54%) than postmeno-
pausal ovaries (7/17, 41%) (Table 2). However, the average
percentage of stained cells was slightly greater in the post-
menopausal (0.76%) than in the premenopausal OEIs
(0.69%). The MIB-1 immunoreactivity was present more
often in the proliferative phase (5/8, 63%) than in the
secretory phase (2/5, 40%; Table 2), and the average per-
centage of stained cells was 0.88 and 0.40%, respectively.
All these differences were, however, based on small num-
bers and were statistically insignificant.
BRCA1 immunoreactivity was found in OEI cells from
8 (27%) of the 30 OEI-containing ovaries examined. Pre-
menopausal OEI-positive ovaries showed slightly greater
proportion of BRCA1 immunoreactivity (4/13, 31%) than
postmenopausal ovaries (4/17, 24%; Table 2). Same was
the average percentage of the stained cells (0.54 and
0.47%). BRCA1 expression was present more often in
the proliferative phase (3/8, 38%) than in the secretory
phase (1/5, 20%; Table 2), with the average percentage of
stained cells being 0.75 and 0.20%, respectively. Again
these differences were based on small numbers and none
are statistically significant. Representative pictures of
BRCA1 staining are shown as Fig. 1 (a and c). Morpho-
logically, some BRCA1-positive cells tended to show
mild nuclear atypia (Fig. 1a).
To examine whether BRCA1 expression is associated
with MIB-1 expression in OEI cells, we used the dual
staining method. We showed that all BRCA1 positive
cells were positive for MIB-1 immunoreactivity (orange
color). Representative pictures of dual staining are
shown as Fig. 1 (b and d). Some MIB-1 immunoreactivity
was also observed in BRCA1-negative cells. A representa-
tive picture with positive MIB-1 and negative BRCA1 is
shown in Fig. 1d.
No BRCA1 and/or MIB-1 expression was detected in
adjacent stroma in any of these 30 ovaries. OSE was
identified in 12 of the 30 OEI-containing ovaries. Two
(17%) of the 12 OSE samples showed occasional dual
BRCA1 and MIB-1 staining, which was less than ob-
served in OEIs. Again the difference was not statistically
significant.
Apoptotic activity was found in OEI cells from 21
(70%) of the 30 OEI-containing ovaries (Table 3). The
apoptotic activity in OEI-containing ovaries was higher
in postmenopausal (15/17, 88%) than in pre-menopausal
(6/13, 46%) women (p < 0.05). This activity also pre-
sented more often in the secretory phase (4/5, 80%) than
Table 1 Presence of OEIs in ovarian sections of pre- and postmenopausal women
Table 2 IHC examination of MIB-1 and BRCA1 expression in
OEIs of certain menopausal status and menstrual cycle phase
MIB-1 BRCA1
Negative Positive (%) Negative Positive (%)
Premenopausal 6 7 (54%) 9 4 (31%)
Postmenopausal 10 7 (41%) 13 4 (24%)
Total 16 14 (47%) 22 8 (27%)
Proliferative phase 3 5 (63%) 5 3 (38%)
Secretory phase 3 2 (40%) 4 1 (20%)
Total 6 7 (54%) 9 4 (31%)
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in the proliferative phase (2/8, 25%) (p < 0.05). The aver-
age percentage of apoptotic cells was lower than 1% of
total OEI cells. By examining the parallel sections from
dual staining slides, apoptotic cells detected from OEIs
were located in different positions from those either
BRCA1 and/or MIB-1 positive cells. Representative
picture of the OEI apoptosis is shown in Fig. 2.
Discussion
OEIs are frequently seen in the ovarian cortex of both
premenopausal and postmenopausal women. In this
study, we examined two sections per ovary and observed
OEIs in 53% of women examined, which is similar to
previous findings [31]. It has been reported that the inci-
dence of OEIs increases with age [31, 32]. In this study,
OEIs were more common in the ovaries of postmeno-
pausal women (58%) than of premenopausal women
(45%), but there was no trend of increasing numbers of
OEIs with age in premenopausal women. The increase
of OEI in postmenopausal women was due to the greater
number of OEIs in younger postmenopausal women.
This pattern is consistent with the results presented by
Mittal et al. [10] and Westhoff et al. [12]. Although it
needs to be confirmed in a larger study with systematic-
ally collected data on the menstrual and reproductive
history of women, this pattern suggests that the OEI
number is not influenced by the number of ovulation
based on this study, but seems increased in the immediate
postmenopausal period (probably followed by regression).
However, this pattern is not in harmony with the known
epidemiologic observations of OEC [8]. The strong
Fig. 1 BRCA1 and MIB-1 dual immunohistochemical stainings in ovarian epithelial inclusions. One epithelial cell of each representative OEIs showed
nuclear immunoreactivity of BRCA1 (a and c, brown in color). These two BRCA1 positive cells were also stained by MIB-1 (b and d, orange in color).
Additional one MIB-1 positive cell was seen (d, red in color on the right side). No cytoplasmic or stromal positivity is seen. (Original magnifications × 200)
Table 3 Apoptotic activity in OEI cells with certain menopausal
status and menstrual cycle phase
Apoptosis
Negative Positive (%)
Premenopausal 7 6 (46%) p = 0.02
Postmenopausal 2 15 (88%)
Total 9 21 (70%)
Proliferative phase 6 2 (25%) p = 0.03
Secretory phase 1 4 (80%)
Total 7 6 (46%)
Fig. 2 Apoptosis in ovarian epithelial inclusions detected by TUNEL
assay. Representative positive apoptotic cell is shown by dark brown
color. Nuclear fragmentation is apparent. No apoptosis is observed in
stromal cells. (Original magnifications × 200)
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correlation we observed for the presence (and number) of
OEI in paired ovaries has been previously reported [12],
which is compatible with the tubal origin of OEIs instead
of coming from ovarian surface epithelia [17, 19, 20].
Previous study of OEIs reported that no mitoses had
been observed [10]. This is the first study to investigate
epithelial cell proliferation within OEIs by an immuno-
histochemical method. From the IHC results, we found
that 0.4 to 0.9% of OEIs were not in the G0 phase of cell
cycle. Although the proportion of proliferative OEI cell
is low, the pattern is similar to what has been observed
in normal breast duct epithelium [33] and it is compat-
ible with the overall incidence of ovarian epithelial
cancer of 0.5 to 0.8% [34]. These observations suggest
that OEI cells do not invariably disappear, but some of
them have a potential of growth. However, it is currently
unknown what factors control the growth of OEIs.
In parallel with cell growth, cell death is another im-
portant parameter for tumor development. In contrast
to proliferative activity in ovarian OEI cells, apoptosis in
the ovaries of postmenopausal women was significantly
more than that in premenopausal women. Although the
overall number of apoptotic cells was small, the
observed higher apoptotic activity in postmenopausal
(low estrogen level) women supports the well-known
epidemiologic phenomenon that the rate of increase in
incidence of OECs is much lower in the postmenopausal
period than in the premenopausal period [8]. In addition
to low estrogen level, high progesterone level (secretory
or luteal phase of menstrual cycle) may promote OEI
cell death via induction of apoptosis. Significantly higher
apoptotic activity within OEIs in secretory phase
suggests that intra-ovarian progesterone may have an
inhibitory role in OEI development. This coincides with
a previous finding of the progesterone-induced dose-
response inhibitory effect in ovarian cystadenoma cells
in vitro [35]. The inhibitory role of progesterone makes
better sense for OEIs, since OEIs are mostly embedded
in ovarian stroma and are undoubtedly exposed to high
levels of progesterone during ovulation. This may
partially explain the epidemiologic observation that
pregnancy and oral contraceptive use are protective for
OEC [2]. However, the molecular mechanisms for
progesterone-related apoptosis in the secretory men-
strual phase remain to be defined.
BRCA1 immunoreactivity was seen about half of the
time in OEI cells as was MIB-1. All BRCA1 positive cells
showed MIB-1 immunoreactivity. This is in agreement
with the previous findings in mouse ovary [36], which
suggests that BRCA1 is expressed in a cell-cycle-
dependent fashion. The expression of BRCA1 mRNA
and protein during different stages of cell cycle is highly
specific, occurring late in the G1 phase and peeking in
the S-phase [37]. BRCA1 expression appears to be a
consequence of cell division. This is supported by the ob-
servation that BRCA1-immunoreactive cells are positive
for MIB-1 expression, which is consistent with the finding
that BRCA1 is expressed in proliferating tissues that are
not hormonally regulated such as liver [38]. Further stud-
ies are needed to determine whether this BRCA1 associ-
ated cell proliferation is indirectly related to hormonal
status, such as effects from autocrine and paracrine
growth factors elaborated by adjacent stromal cells. In our
previous study of BRCA1 and MIB-1 expression in ovar-
ian epithelial tumors, we found that BRCA1 was highly
correlated with MIB-1 expression in cystadenomas and
borderline tumors [25]. If we believe that ovarian epithe-
lial tumorigenesis is a multi-step process, our finding that
high correlation of BRCA1 and MIB-1 in OEIs supports
the assumption that ovarian epithelial tumors at least
some of them may arise from OEIs. Although small
percentage (<1%) of the cells were seemingly difficult to
explain all existing OEC developing theories, considering
the fact that OEC development is a relatively long process,
minor imbalance between cell proliferation and cell death
in OEIs under the influence of hormonal status may, in a
long term run, play an important role in the process of
ovarian epithelial tumorigenesis.
It is biologically known that BRCA1 acts in concert
with DNA repair enzymes to maintain the integrity of
the genome during cell growth [39, 40]. Some BRCA1-
positive cells we observed showed mild nuclear atypia.
This is likely to be the same phenomenon observed in
Werness’ report [16], in which they studied OEIs in
ovaries removed prophylactically from women with a
family history of ovarian cancer and found more irregular
outlines of the epithelial nuclei compared to the control
group. These irregular nuclear outlines appear to be
equivalent to our ‘mild nuclear atypia’. However, whether
DNA damage is present in these mild atypical cells re-
mains to be defined. BRCA1 immunoreactivity in normal
ovary was concentrated in the nuclei of granulosa and
theca interna cells of developing follicles, the vast majority
of which were BRCA1 positive; this is consistent with ob-
servations made on mouse ovary [36]. BRCA1 immunor-
eractivity was also mainly observed in the nuclei of OEI
cells. We did not detect BRCA1 immunoreactivity in the
stroma of normal ovaries. The non-detectable or rare im-
munoreactivity of BRCA1 in ovarian stroma is possibly
due to the mitotically almost inactive nature of this tissue.
This finding is in contrast to that of Wilson et al. [29] who
reported that BRCA1 was expressed uniformly in all types
of ovarian cells. Further studies are needed to clarify these
discrepant findings.
Conclusions
In summary, this is the first study on BRCA1 expression,
cellular proliferation and apoptosis in OEIs of patients
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without known history of ovarian cancer. BRCA1
expression is closely related to cellular proliferation in
OEI cells. Apoptosis of OEI cells is found more in
secretory phase of the menstrual cycle and in postmeno-
pausal status. Imbalance between cell proliferation and
death within OEI under the influence of hormones may
be important for OEC development. Further studies are
needed to identify the factors for maintaining their
survival and promoting their growth.
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